Literature DB >> 14523926

The molecular basis for A-site mutations conferring aminoglycoside resistance: relationship between ribosomal susceptibility and X-ray crystal structures.

Peter Pfister1, Sven Hobbie, Quentin Vicens, Erik C Böttger, Eric Westhof.   

Abstract

Aminoglycoside antibiotics target the 16S ribosomal RNA (rRNA) bacterial A site and induce misreading of the genetic code. Point mutations of the ribosomal A site may confer resistance to aminoglycoside antibiotics. The influence of bacterial mutations (introduced by site-directed mutagenesis) on ribosomal drug susceptibility was investigated in vivo by determination of minimal inhibitory concentrations. To determine the origin of the various resistance phenotypes at a molecular level, the in vivo results were compared with the previously published crystal structures of paromomycin, tobramycin, and geneticin bound to oligonucleotides containing the minimal A site. Two regions appear crucial for binding in the A site: the single adenine residue at position 1408 and the non-Watson-Crick U1406.U1495 pair. The effects of mutations at those positions are modulated by the nature of the substituent at position 6' (either hydroxy or ammonium group) on ring I, by the number of positive charges on the antibiotic, and by the linkage between rings I and III (either 4,5 or 4,6). In particular, the analysis demonstrates: 1) that the C1409-G1491 to A1409-U1491 polymorphism (observed in 15 % of bacteria) is not associated with resistance, which indicates that it does not affect the stacking of ring I on residue 1491, 2) that the high-level resistance to 6'-NH3+ aminoglycosides exhibited by the A1408G mutation most probably results from the inability of ring I forming a pseudo base pair with G1408, which prevents its insertion inside the A site helix, and 3) that mutations of the uracil residues forming the U1406.U1495 pair either to cytosine or to adenine residues mostly confer low to moderate levels of drug resistance, whereas the U1406C/U1495A double mutation confers high-level resistance (except for neomycin), which suggests that aminoglycoside binding to the wild-type A site and its functional consequences strongly depend on a particular geometry of the U1406.U1495 pair. The relationships between the resistance phenotypes observed in vivo and the interactions described at the molecular level define the biological importance of the different structural interactions observed by X-ray crystallography studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523926     DOI: 10.1002/cbic.200300657

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  43 in total

Review 1.  Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases.

Authors:  Jill E Clarridge
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

2.  A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.

Authors:  Guojun Wang; Takashi Inaoka; Susumu Okamoto; Kozo Ochi
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

3.  Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors.

Authors:  Yuefen Zhou; Chun Chow; Douglas E Murphy; Zhongxiang Sun; Thomas Bertolini; Jamie M Froelich; Stephen E Webber; Thomas Hermann; Daniel Wall
Journal:  Bioorg Med Chem Lett       Date:  2008-04-13       Impact factor: 2.823

4.  Analysis of the contribution of individual substituents in 4,6-aminoglycoside-ribosome interaction.

Authors:  Sven N Hobbie; Peter Pfister; Christian Brüll; Eric Westhof; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Phylogenetic sequence variations in bacterial rRNA affect species-specific susceptibility to drugs targeting protein synthesis.

Authors:  Subramanian Akshay; Mihai Bertea; Sven N Hobbie; Björn Oettinghaus; Dimitri Shcherbakov; Erik C Böttger; Rashid Akbergenov
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

6.  Design, Multigram Synthesis, and in Vitro and in Vivo Evaluation of Propylamycin: A Semisynthetic 4,5-Deoxystreptamine Class Aminoglycoside for the Treatment of Drug-Resistant Enterobacteriaceae and Other Gram-Negative Pathogens.

Authors:  Takahiko Matsushita; Girish C Sati; Nuwan Kondasinghe; Michael G Pirrone; Takayuki Kato; Prabuddha Waduge; Harshitha Santhosh Kumar; Adrian Cortes Sanchon; Malgorzata Dobosz-Bartoszek; Dimitri Shcherbakov; Mario Juhas; Sven N Hobbie; Thomas Schrepfer; Christine S Chow; Yury S Polikanov; Jochen Schacht; Andrea Vasella; Erik C Böttger; David Crich
Journal:  J Am Chem Soc       Date:  2019-03-13       Impact factor: 15.419

7.  When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy.

Authors:  Moran Shalev; Timor Baasov
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

8.  Studying modification of aminoglycoside antibiotics by resistance-causing enzymes via microarray.

Authors:  Matthew D Disney
Journal:  Methods Mol Biol       Date:  2012

9.  Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.

Authors:  Jun-ichi Wachino; Keigo Shibayama; Hiroshi Kurokawa; Kouji Kimura; Kunikazu Yamane; Satowa Suzuki; Naohiro Shibata; Yasuyoshi Ike; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

10.  Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity.

Authors:  Hua Fan-Minogue; David M Bedwell
Journal:  RNA       Date:  2007-11-14       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.